Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

CapMan Q2’25: Interesting times ahead

CapMan

No major surprises in CapMan's Q2 report, and the clear earnings miss was entirely attributable to investment portfolio returns. Relative to AUM, CapMan’s price tag is small. However, the challenge is that AUM performance is far from its potential. Analyst Sauli Vilén summarizes.

Read the latest report: Sales performance needs to be proven in second half

Stay up to date
Analyst Interviews

Recent videos

Herantis Pharma Plc, Phase 1b biomarker data webcast
08.01.2026 klo 12.00 Herantis Pharma
Investor Day | Nov. 24, 2025
23.12.2025 klo 12.00 United Bankers
Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025 klo 12.00 Talenom
Investing in the life science sector
18.12.2025 klo 08.47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
16.12.2025 klo 09.30 Aiforia Technologies
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.